


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**ENTERING INTO GLOBAL COLLABORATION AGREEMENT WITH BIOSION AND**  
**ACLARIS THERAPEUTICS**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Group and Biosion, Inc. (“**Biosion**”) entered into a global collaboration agreement with Aclaris Therapeutics, Inc. (“**Aclaris Therapeutics**”) for the jointly developed “BSI-045B (TQC2731)”, an anti-TSLP monoclonal antibody.

Simultaneously with the collaboration agreement, Aclaris Therapeutics entered into a license agreement with Biosion for the exclusive rights to develop, manufacture and commercialize BSI-045B (TQC2731) and another preclinical product worldwide (excluding Mainland China, Macau, Hong Kong and Taiwan). In consideration for the license agreement and collaboration agreement, Aclaris Therapeutics agreed to pay, in the aggregate, a portion of which is payable to the Group, over US\$40 million cash payment as upfront license fee and reimbursement for certain development costs and drug product materials costs, 19.9% shares of common stock of Aclaris Therapeutics (stock code NASDAQ: ACRS, based on the closing price on 4 December 2024, the total value is approximately US\$54 million), potential regulatory and sales milestone payments of over US\$900 million in the aggregate, as well as a single digit royalty based upon a percentage of annual net sales.

**About BSI-045B (TQC2731)**

BSI-045B (TQC2731) is a humanized monoclonal antibody that specifically binds to thymic stromal lymphopoietin (TSLP), which can prevent immune cells targeted by TSLP from releasing proinflammatory cytokines. Currently, BSI-045B (TQC2731) is being evaluated in Phase III clinical trials in China and Phase II clinical trials worldwide, with indications including asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis (“**AD**”).

In a completed, proof-of-concept, single-arm Phase IIa study in 22 subjects in the US, BSI-045B (TQC2731) demonstrated a pharmacodynamic, safety and efficacy profile for moderate to severe AD, which supports its potential as a first-in-class therapy in AD.

### **About Biosion**

Biosion is a global clinical-stage biotechnology company focused on developing innovative antibody-based therapies to improve outcomes for patients with immune and oncologic diseases. Leveraging its proprietary technologies such as the H<sup>3</sup> antibody discovery platform, SynTracer<sup>®</sup> HT endocytosis platform, and Flexibody<sup>®</sup> bispecific platform, Biosion creates highly differentiated medicines to address significant unmet medical needs worldwide. With its “discover-development-partnership” model, the company has forged 10 global collaborations, advancing 7 clinical-stage assets, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADC). Biosion operates across the US, China, and Australia.

### **About Aclaris Therapeutics**

Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 5 December 2024

*As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*